Innovation1 Biotech Stock Performance
| IVBT Stock | USD 0 0.00 0.00% |
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Innovation1 Biotech are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Innovation1 Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental drivers, Innovation1 Biotech is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 137.5 K | |
| Price Earnings Ratio | 0.0406 | |
| Free Cash Flow | -3.1 M |
Innovation1 |
Innovation1 Biotech Relative Risk vs. Return Landscape
If you would invest 0.10 in Innovation1 Biotech on August 28, 2024 and sell it today you would earn a total of 0.00 from holding Innovation1 Biotech or generate 0.0% return on investment over 90 days. Innovation1 Biotech is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc stocks are less volatile than Innovation1, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Innovation1 Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Innovation1 Biotech's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Innovation1 Biotech, and traders can use it to determine the average amount a Innovation1 Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| IVBT |
Based on monthly moving average Innovation1 Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Innovation1 Biotech by adding Innovation1 Biotech to a well-diversified portfolio.
Innovation1 Biotech Fundamentals Growth
Innovation1 OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Innovation1 Biotech, and Innovation1 Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Innovation1 OTC Stock performance.
| Return On Equity | -1.79 | |||
| Return On Asset | -0.0781 | |||
| Current Valuation | 1.83 M | |||
| Shares Outstanding | 20.02 M | |||
| Price To Earning | 0.01 X | |||
| Price To Book | 0.05 X | |||
| EBITDA | (38.33 M) | |||
| Cash And Equivalents | 636.16 K | |||
| Cash Per Share | 0.03 X | |||
| Total Debt | 554.4 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 0.10 X | |||
| Cash Flow From Operations | (3.13 M) | |||
| Earnings Per Share | 5.54 X | |||
| Total Asset | 43.96 M | |||
About Innovation1 Biotech Performance
Assessing Innovation1 Biotech's fundamental ratios provides investors with valuable insights into Innovation1 Biotech's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Innovation1 Biotech is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Innovation1 Biotech Inc. operates as a small molecule drug discovery company. The company was founded in 2014 and is based in New York, New York. Innovation1 Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.Things to note about Innovation1 Biotech performance evaluation
Checking the ongoing alerts about Innovation1 Biotech for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Innovation1 Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Innovation1 Biotech generated a negative expected return over the last 90 days | |
| Innovation1 Biotech has some characteristics of a very speculative penny stock | |
| Innovation1 Biotech currently holds 554.4 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Innovation1 Biotech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Innovation1 Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Innovation1 Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovation1 Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovation1 to invest in growth at high rates of return. When we think about Innovation1 Biotech's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (40.88 M) with loss before overhead, payroll, taxes, and interest of (17 K). | |
| Innovation1 Biotech currently holds about 636.16 K in cash with (3.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 75.0% of Innovation1 Biotech shares are held by company insiders |
- Analyzing Innovation1 Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Innovation1 Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Innovation1 Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Innovation1 Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Innovation1 Biotech's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Innovation1 Biotech's otc stock. These opinions can provide insight into Innovation1 Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Innovation1 OTC Stock Analysis
When running Innovation1 Biotech's price analysis, check to measure Innovation1 Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovation1 Biotech is operating at the current time. Most of Innovation1 Biotech's value examination focuses on studying past and present price action to predict the probability of Innovation1 Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovation1 Biotech's price. Additionally, you may evaluate how the addition of Innovation1 Biotech to your portfolios can decrease your overall portfolio volatility.